Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heamatology

- PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease

- PMLiVE

AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

Celgene building

FDA turns down Celgene’s filing for multiple sclerosis drug

The application needs additional pharmacology information according to the US agency

- PMLiVE

Shaky mid-stage data won’t halt Celgene’s plans for Otezla

The US biotech will continue to test the drug in patients with UC and Behçet’s disease

Celgene building

Celgene’s triple multiple myeloma therapy clears phase III trial

The biotech says the combo hit its OPTIMISMM primary endpoint

Celgene’s CEO Mark Alles is appointed as chairman

He succeeds Bob Hugin who is retiring from the pharma firm

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

Celgene building

Celgene reaches $9bn agreement to buy Juno

Acquires its blood cancer CAR-T candidate in the process

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy picks up another indication in Europe

The EC licenses the immuno-oncology treatment for children with skin cancer

- PMLiVE

MHRA: No change for pre-Brexit products after UK exits the EU

And UK plans to follow EU rules for an implementation period after March 2019

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links